NCT03683225View on ClinicalTrials.gov

A Study to Evaluate in Patients With Parkinsonian Type Disorders

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 1, 2019

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions
Idiopathic Parkinson Disease
Interventions
COMBINATION_PRODUCT

CTC-413

pramipexole ER, given with aprepitant

Trial Locations (1)

48334

Quest Research, Farmington Hills

Sponsors
All Listed Sponsors
lead

Chase Therapeutics Corporation

INDUSTRY

NCT03683225 - A Study to Evaluate in Patients With Parkinsonian Type Disorders | Biotech Hunter | Biotech Hunter